Formulation and Drug Delivery

The advantages of single-use systems become clear as they become more broadly implemented.

ChargePoint Technology is expanding its US presence by opening a new office in San Francisco.

GSK plans to deliver up to 40 million doses of its quadrivalent flu vaccine for the 2017–2018 season.

The company has entered into a settlement agreement with generic-drug companies to resolve patent litigation.

Pfizer’s new format of ibuprofen (AdvilR Liqui-GelsR Minis) uses Catalent’s softgel technology to deliver the formulation in a more concentrated fill, resulting in smaller capsules.

New study shows that an antimicrobial peptide packaged in a silicon nanoparticle significantly reduced bacteria load in the lungs of mice infected with Pseudomonas aeruginosa.

The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio

ABEC increases the maximum capacity of its Custom Single Run Bioreactors to 4000 L, doubling the industry standard.

GE Healthcare’s Dharmacon business and CordenPharma contract manufacturing enter a strategic collaboration to accelerate the oligonucleotide development process.

After FDA found a “significant shift in the route of abuse,” Endo voluntarily removes OPANA ER from the market.

Sienna Biopharmaceuticals has filed for an IPO, expecting to raise over $74 million

A Supreme Court decision and improvements in analytical processes may speed the biosimilar approval process.

Samsung BioLogics signs $55.5 million agreement to manufacture tildrakizumab for Sun Pharma.

The Spanish CDMO has installed a new automatic capsule filling machine at its EU GMP-approved plant in Pamplona, Spain

Industry experts discuss the single-use revolution and changes to upstream and downstream processing equipment.

The BIOSTAT STR single-use bioreactor family from Sartorius Stedim Biotech is based on a conventional stirred-tank design.

Poly(lactide-glycolide) has been used for drug-delivery applications because of its beneficial physicochemical properties, long safety record, and reliable commercial supply.

Materials and equipment innovations have advanced tablet coating from sugar to copolymers and simplified pharma production.

New ADC therapies must overcome manufacturing challenges to reach market.

As commercial manufacturing considers single-use materials, a look shows how industry moved to the technology.

The more pharma science and technology change, the more business and policy concerns stay the same.

Biotech-based therapies and a move to single-use processes highlight recent industry changes.

ISPE measures impact of biotechnology and globalization on personalized medicine.

Drug costs, biosimilars, and cloud-based technologies will shape the pharmaceutical industry in the years to come.

Advancements in cell culture and protein technology have opened the door for new therapies.

Pharma’s test of continuous manufacturing is starting with oral solid-dosage forms.

Greater transparency and reliability of information are needed in the quality assessments of biosimilars.

The directorate highlights its 2016 achievements.

Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.

BIO report measures decade-long investment and acquisition trends for emerging biotech companies.